Latest News

Naltrexone implant helps HIV patients prevent opioid relapse

(HealthDay)—Slow-release implantable naltrexone is associated with better outcomes than the oral drug for HIV-positive patients with an opioid addiction, according to a study published in the April issue of The Lancet HIV.

Source link

Related posts

Opinion: China isn’t yet ready to conduct clinical trials for the pharma industry


Medical News Today: New chemical causes deadly brain cancer to self-destruct


Opinion: 11-country survey of primary care physicians shows where U.S. is lagging and keeping pace


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy